Compare PWR & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PWR | REGN |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0B | 73.9B |
| IPO Year | 1998 | 1991 |
| Metric | PWR | REGN |
|---|---|---|
| Price | $421.99 | $747.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 23 |
| Target Price | $422.95 | ★ $795.74 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 10-30-2025 | 02-03-2026 |
| Dividend Yield | 0.10% | ★ 0.47% |
| EPS Growth | ★ 24.72 | 2.88 |
| EPS | 6.75 | ★ 41.59 |
| Revenue | ★ $27,191,171,000.00 | $14,247,800,000.00 |
| Revenue This Year | $19.56 | $1.95 |
| Revenue Next Year | $12.24 | $5.47 |
| P/E Ratio | $62.45 | ★ $18.00 |
| Revenue Growth | ★ 18.72 | 2.89 |
| 52 Week Low | $227.08 | $476.49 |
| 52 Week High | $473.99 | $790.98 |
| Indicator | PWR | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 62.66 |
| Support Level | $411.41 | $739.23 |
| Resistance Level | $441.41 | $757.35 |
| Average True Range (ATR) | 14.85 | 18.64 |
| MACD | -5.05 | -1.75 |
| Stochastic Oscillator | 21.14 | 98.51 |
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two segments: electric infrastructure and underground utility and infrastructure.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).